Chembio Diagnostics Inc. (NASDAQ: CEMI) is 13.47% higher on its value in year-to-date trading and has touched a low of $2.25 and a high of $15.89 in the current 52-week trading range. The CEMI stock was last observed hovering at around $5.39 in the last trading session, with the day’s gains setting it 1.02% off its average median price target of $9.00 for the next 12 months. It is also 35.9% off the consensus price target high of $10.00 offered by 3 analysts, but current levels are 19.88% higher than the price target low of $8.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $6.41, the stock is 23.48% and 21.44% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.81 million and changing 18.92% at the moment leaves the stock 0.27% off its SMA200. CEMI registered 29.57% gain for a year compared to 6-month gain of 5.69%. The firm has a 50-day simple moving average (SMA 50) of $5.60 and a 200-day simple moving average (SMA200) of $4.94.
The stock witnessed a -8.64% loss in the last 1 month and extending the period to 3 months gives it a 13.24%, and is 8.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.96% over the week and 6.99% over the month.
Chembio Diagnostics Inc. (CEMI) has around 295 employees, a market worth around $107.26M and $29.10M in sales. Profit margin for the company is -76.50%. Distance from 52-week low is 184.89% and -59.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.50%).
Chembio Diagnostics Inc. (CEMI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Chembio Diagnostics Inc. (CEMI) is a “Overweight”. 3 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Chembio Diagnostics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.28 with sales reaching $5.77M over the same period.The EPS is expected to shrink by -48.00% this year, but quarterly earnings will post -18.70% year-over-year. Quarterly sales are estimated to shrink -15.80% in year-over-year returns.
Chembio Diagnostics Inc. (CEMI) Top Institutional Holders
91 institutions hold shares in Chembio Diagnostics Inc. (CEMI), with 2.8M shares held by insiders accounting for 13.89% while institutional investors hold 39.19% of the company’s shares. The shares outstanding are 20.11M, and float is at 17.37M with Short Float at 22.28%. Institutions hold 33.75% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 1.31 million shares valued at $6.35 million. The investor’s holdings represent 6.47% of the CEMI Shares outstanding. As of Sep 29, 2020, the second largest holder is Blackrock Inc. with 1.17 million shares valued at $5.68 million to account for 5.80% of the shares outstanding. The other top investors are Segall Bryant & Hamill LLC which holds 0.63 million shares representing 3.11% and valued at over $3.05 million, while Royce & Associates LP holds 2.44% of the shares totaling 0.49 million with a market value of $2.39 million.
Chembio Diagnostics Inc. (CEMI) Insider Activity
A total of 0 insider transactions have happened at Chembio Diagnostics Inc. (CEMI) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Chembio Diagnostics Inc. (CEMI): Who are the competitors?
The company’s main competitors (and peers) include OraSure Technologies Inc. (OSUR) that is 55.89% higher over the past 12 months. Bio-Rad Laboratories Inc. (BIO) is 57.31% up on the 1-year trading charts. Short interest in the company’s stock has risen 5.0% from the last report on Nov 29, 2020 to stand at a total of 3.61 million short shares sold with a short interest ratio of 1.74.